IP Library › Granted Patent US 9,763,936
Granted Patent B2
US 9,763,936 · App. 14/809,862 · Granted Sep 19, 2017

Flibanserin for the treatment of urinary incontinence and related diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,763,936
App. No.
14/809,862
Granted
Sep 19, 2017
Kind
B2
Abstract

The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.

Claims (17)

1. A method for treating or reducing urinary incontinence comprising administering a therapeutically effective amount of Flibanserin 1, or a pharmacologically acceptable acid addition salt, hydrate, or solvate thereof.

2. The method for treating or reducing urinary incontinence according to claim 1 , further comprising administering an active ingredient 2, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

3. The method for treating or reducing urinary incontinence according to claim 1 , wherein the urinary incontinence is overactive bladder syndrome.

4. The method for treating or reducing urinary incontinence according to claim 2 , wherein the urinary incontinence is overactive bladder syndrome.

5. The method for treating or reducing urinary incontinence according to claim 1 , wherein the urinary incontinence is urgency.

6. The method for treating or reducing urinary incontinence according to claim 1 , wherein the urinary incontinence is urge urinary incontinence.

7. The method for treating or reducing urinary incontinence according to claim 1 , wherein the urinary incontinence is stress urinary incontinence.

8. The method for treating or reducing urinary incontinence according to claim 1 , wherein the urinary incontinence is mixed urinary incontinence.

9. The method for treating reducing urinary incontinence according to claim 2 , wherein the active ingredient 2 is an antimuscarinic agent 2a, vasopressin agonist 2b, Serotonin/Noradrenaline modulator 2c, or β3 agonist 2d.

10. The method for treating or reducing urinary incontinence according to claim 9 , wherein the active ingredient 2 is an antimuscarinic agent 2a.

11. The method for treating or reducing urinary incontinence according to claim 10 , wherein the antimuscarinic agent 2a is Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin, or Trospium, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

12. The method for treating or reducing urinary incontinence according to claim 9 , wherein the active ingredient 2 is a vasopressin agonist 2b.

13. The method for treating or reducing urinary incontinence according to claim 12 , wherein the vasopressin agonists 2b is desmopressin, a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

14. The method for treating or reducing urinary incontinence according to claim 9 , wherein the active ingredient 2 is a Serotonin/Noradrenaline modulator 2c.

15. The method for treating or reducing urinary incontinence according to claim 14 , wherein the Serotonin/Noradrenaline modulator 2c is Venlafaxine, Duloxetine, Reboxetine, or Cizoliritine or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

16. The method for treating or reducing urinary incontinence according to claim 9 , wherein the active ingredient 2 is a β3 agonist 2d.

17. The method for treating or reducing urinary incontinence according to claim 16 , wherein the β3 agonist 2d is AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A, or CGP-12177A, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0194 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY INTEREST Recorded Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
SECURITY AGREEMENT Recorded Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →